-
公开(公告)号：US20240309016A1
公开(公告)日：2024-09-19
申请号：US18606857
申请日：2024-03-15
发明人： Mitsunori KONO , Yusuke SASAKI , Yuya OGURO , Zenichi IKEDA , Osamu KUBO , Masaki SETO , Toru YAMASHITA , Makoto KAMATA , Kenjiro SATO , Matthew Thomas REYNOLDS , Kazuaki TAKAMI , Asato KINA , Takafumi YUKAWA , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Keiko KAKEGAWA , Takuto KOJIMA , Florian PÜNNER , Masataka MURAKAMI , Takahiko TANIGUCHI , Tatsuki KOIKE , Yuichi KAJITA , Yuhei MIYANOHANA , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Yasushi HATTORI , Eiji KIMURA , Martin Alexander PAWLICZEK , Marilena PIRA , Shuhei IKEDA , Noriyuki TEZUKA , Yoshikazu WATANABE , Kevin CURRAN , Nicolle DOERING , Maria HOPKINS , Ben JOHNSON , Andre KIRYANOV , Jon LAM , Sean MURPHY , Natasha O'ROURKE , Holly REICHARD , Paul TANIS , Yunlong ZHANG
IPC分类号： C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
CPC分类号： C07D498/14 , A61K31/407 , A61K31/437 , A61P25/26 , C07D498/04
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20160355494A1
公开(公告)日：2016-12-08
申请号：US15117538
申请日：2015-02-12
IPC分类号： C07D307/81
CPC分类号： C07D307/81
摘要： A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
-
公开(公告)号：US20240217957A1
公开(公告)日：2024-07-04
申请号：US18522917
申请日：2023-11-29
发明人： Asato KINA , Zenichi IKEDA , Mitsunori KONO , Yuya OGURO , Osamu KUBO , Toru YAMASHITA , Kazuaki TAKAMI , Takafumi YUKAWA , Masaki SETO , Makoto KAMATA , Kenjiro SATO , Masataka MURAKAMI , Yusuke SASAKI , Matthew Thomas REYNOLDS , Minoru NAKAMURA , Taku KAMEI , Hiroyuki KAKEI , Fumie YAMAGUCHI , Tomohiro OHASHI , Takuto KOJIMA , Keiko KAKEGAWA , Florian PÜNNER , Shinji NAKAMURA , Nao MORISHITA , Tadashi HIDAKA , Sachie TAKASHIMA , Takahiko TANIGUCHI
IPC分类号： C07D413/04 , A61P25/00 , C07D413/14
CPC分类号： C07D413/04 , A61P25/00 , C07D413/14
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I):
wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.-
公开(公告)号：US20210094944A1
公开(公告)日：2021-04-01
申请号：US17030504
申请日：2020-09-24
发明人： Masahiro ITO , Hideyuki SUGIYAMA , Takeshi YAMAMOTO , Keiko KAKEGAWA , Jinxing LI , Junsi WANG , Takahito KASAHARA , Masato YOSHIKAWA
IPC分类号： C07D413/14 , C07D413/10 , A61P25/28
摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US20240343721A1
公开(公告)日：2024-10-17
申请号：US18635839
申请日：2024-04-15
发明人： Masahiro ITO , Hideyuki SUGIYAMA , Takeshi YAMAMOTO , Keiko KAKEGAWA , Jinxing LI , Junsi WANG , Takahito KASAHARA , Masato YOSHIKAWA
IPC分类号： C07D413/14 , A61P25/28 , C07D413/10
CPC分类号： C07D413/14 , A61P25/28 , C07D413/10
摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US20220289679A1
公开(公告)日：2022-09-15
申请号：US17630442
申请日：2020-07-28
发明人： Yuta TANAKA , Yuta TANAKA , Keiko KAKEGAWA , Takahito KASAHARA , Fumiaki KIKUCHI , Takeshi YAMAMOTO , Tomohiro OHASHI , Zenichi IKEDA , Florian PUENNER , Minoru NAKAMURA , Kazuaki TAKAMI , Masataka MURAKAMI , Masaki DAINI , Masaki SETO , Satoshi MIKAMI , Minoru SASAKI
IPC分类号： C07D213/82 , C07D401/12 , C07D471/04 , C07D413/12 , C07D405/14 , C07D401/14 , C07D237/14 , C07D405/12
摘要： The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20160347724A1
公开(公告)日：2016-12-01
申请号：US15117539
申请日：2015-02-12
IPC分类号： C07D261/04 , C07D413/10
CPC分类号： C07D261/04 , C07D413/10
摘要： A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
-
公开(公告)号：US20230183227A1
公开(公告)日：2023-06-15
申请号：US17952546
申请日：2022-09-26
发明人： Masahiro ITO , Hideyuki SUGIYAMA , Takeshi YAMAMOTO , Keiko KAKEGAWA , Jinxing LI , Junsi WANG , Takahito KASAHARA , Masato YOSHIKAWA
IPC分类号： C07D413/14 , A61P25/28 , C07D413/10
CPC分类号： C07D413/14 , A61P25/28 , C07D413/10
摘要： The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I)
wherein each symbol is as defined in the description, or a salt thereof.-
公开(公告)号：US20220098180A1
公开(公告)日：2022-03-31
申请号：US17426971
申请日：2020-01-29
发明人： Masahiro ITO , Takeshi YAMAMOTO , Keiko KAKEGAWA , Hideyuki SUGIYAMA , Tohru MIYAZAKI , Yasuyoshi ARIKAWA , Tomohiro OKAWA , Jinichi YONEMORI , Osamu KUBO , Akinori TOITA , Takuto KOJIMA , Fumiaki KIKUCHI , Minoru SASAKI , Misaki HOMMA , Yasuhiro IMAEDA , Hironobu MAEZAKI , Shiinobu SASAKI , Ayumu SATO , Hirotaka KAMITANI , Yasutomi ASANO , Hironori KOKUBO , Masato YOSHIKAWA
IPC分类号： C07D413/10 , C07D271/06 , C07D413/14 , C07D417/14
摘要： The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20210087186A1
公开(公告)日：2021-03-25
申请号：US16961476
申请日：2019-01-30
发明人： Yuta TANAKA , Tomohiro OHASHI , Zenichi IKEDA , Yuta TANAKA , Florian PÜNNER , Takeshi YAMAMOTO , Keiko KAKEGAWA , Fumiaki KIKUCHI , Nao MORISHITA , Takahito KASAHARA , Masaki SETO , Minoru NAKAMURA , Kazuaki TAKAMI , Masataka MURAKAMI , Masaki DAINI , Satoshi MIKAMI , Minoru SASAKI
IPC分类号： C07D471/04 , C07D495/04 , C07D487/04 , C07D491/048 , C07D519/00
摘要： The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.017 秒)
